Stocks · Health care · Biological Products, (No Diagnostic Substances)

REPLIGEN CORP

RGEN Clue Score51
United States Fiscal year ends December CIK 0000730272 Results filed 27 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Olivier Loeillot
4 Sep 2026
Chief Executive Officer
Sold on a plan
3,035
$165.90
$503.51K
Jason K Garland
16 Jul 2026
CFO
Sold on a plan
530
$150.00
$79.50K
Jason K Garland
25 Jun 2026
CFO
Sold on a plan
733
$145.00
$106.29K
Olivier Loeillot
21 Apr 2026
Chief Executive Officer
Sold on a plan
3,832
$140.00
$536.48K
Olivier Loeillot
25 Nov 2025
Chief Executive Officer
Sold on a plan
7,041
$170.00
$1.20M
Anthony Hunt
15 May 2025
Director
Sold on a plan
7
$127.00
$889.00
Anthony Hunt
15 May 2025
Director
Sold on a plan
268
$125.20
$33.55K
Anthony Hunt
15 May 2025
Director
Sold on a plan
6,533
$124.34
$812.31K
Anthony Hunt
15 May 2025
Director
Sold on a plan
17,596
$123.57
$2.17M
Anthony Hunt
15 May 2025
Director
Sold on a plan
2,043
$122.66
$250.59K
Anthony Hunt
21 May 2024
Chief Executive Officer
Sold on a plan
969
$171.03
$165.73K
Anthony Hunt
21 May 2024
Chief Executive Officer
Sold on a plan
3,925
$170.04
$667.41K
Anthony Hunt
21 May 2024
Chief Executive Officer
Sold on a plan
2,963
$169.27
$501.55K
Anthony Hunt
21 May 2024
Chief Executive Officer
Sold on a plan
3,933
$168.33
$662.04K
Anthony Hunt
21 May 2024
Chief Executive Officer
Sold on a plan
4,008
$167.05
$669.54K
Anthony Hunt
21 May 2024
Chief Executive Officer
Sold on a plan
4,274
$166.36
$711.02K
Showing 250 of 369 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 354
Amendments (4/A) skipped 15
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 16
Sales straight out of an exercise 160
Sales at will 170
Transactions with no price 0
Shares from compensation/vesting 3,091,951
Sales filed before the plan box existed 166
History held since 6 Dec 2006